CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.14 billion. The enterprise value is $1.99 billion.
| Market Cap | 1.14B |
| Enterprise Value | 1.99B |
Important Dates
The next confirmed earnings date is Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CONMED has 30.14 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 30.14M |
| Shares Outstanding | 30.14M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 114.60% |
| Float | 29.86M |
Valuation Ratios
The trailing PE ratio is 25.11 and the forward PE ratio is 8.71. CONMED's PEG ratio is 1.66.
| PE Ratio | 25.11 |
| Forward PE | 8.71 |
| PS Ratio | 0.83 |
| Forward PS | 0.82 |
| PB Ratio | 1.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.57 |
| P/OCF Ratio | 6.69 |
| PEG Ratio | 1.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.87, with an EV/FCF ratio of 13.19.
| EV / Earnings | 42.28 |
| EV / Sales | 1.45 |
| EV / EBITDA | 9.87 |
| EV / EBIT | 15.47 |
| EV / FCF | 13.19 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.86.
| Current Ratio | 2.14 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 4.17 |
| Debt / FCF | 5.88 |
| Interest Coverage | 4.14 |
Financial Efficiency
Return on equity (ROE) is 4.72% and return on invested capital (ROIC) is 4.60%.
| Return on Equity (ROE) | 4.72% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 4.60% |
| Return on Capital Employed (ROCE) | 6.39% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | $352,493 |
| Profits Per Employee | $12,065 |
| Employee Count | 3,900 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, CONMED has paid $24.06 million in taxes.
| Income Tax | 24.06M |
| Effective Tax Rate | 33.83% |
Stock Price Statistics
The stock price has decreased by -21.82% in the last 52 weeks. The beta is 0.99, so CONMED's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -21.82% |
| 50-Day Moving Average | 39.62 |
| 200-Day Moving Average | 44.94 |
| Relative Strength Index (RSI) | 51.25 |
| Average Volume (20 Days) | 417,294 |
Short Selling Information
The latest short interest is 846,967, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.84% |
| Short Ratio (days to cover) | 5.21 |
Income Statement
In the last 12 months, CONMED had revenue of $1.37 billion and earned $47.06 million in profits. Earnings per share was $1.51.
| Revenue | 1.37B |
| Gross Profit | 740.58M |
| Operating Income | 128.57M |
| Pretax Income | 71.12M |
| Net Income | 47.06M |
| EBITDA | 201.65M |
| EBIT | 128.57M |
| Earnings Per Share (EPS) | $1.51 |
Balance Sheet
The company has $40.82 million in cash and $887.49 million in debt, with a net cash position of -$846.67 million or -$28.09 per share.
| Cash & Cash Equivalents | 40.82M |
| Total Debt | 887.49M |
| Net Cash | -846.67M |
| Net Cash Per Share | -$28.09 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 33.36 |
| Working Capital | 357.82M |
Cash Flow
In the last 12 months, operating cash flow was $170.69 million and capital expenditures -$19.81 million, giving a free cash flow of $150.88 million.
| Operating Cash Flow | 170.69M |
| Capital Expenditures | -19.81M |
| Depreciation & Amortization | 73.08M |
| Net Borrowing | -74.59M |
| Free Cash Flow | 150.88M |
| FCF Per Share | $5.01 |
Margins
Gross margin is 53.87%, with operating and profit margins of 9.35% and 3.42%.
| Gross Margin | 53.87% |
| Operating Margin | 9.35% |
| Pretax Margin | 5.17% |
| Profit Margin | 3.42% |
| EBITDA Margin | 14.67% |
| EBIT Margin | 9.35% |
| FCF Margin | 10.98% |
Dividends & Yields
This stock pays an annual dividend of $0.40, which amounts to a dividend yield of 1.06%.
| Dividend Per Share | $0.40 |
| Dividend Yield | 1.06% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 26.49% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 1.06% |
| Earnings Yield | 4.12% |
| FCF Yield | 13.20% |
Analyst Forecast
The average price target for CONMED is $48.00, which is 26.62% higher than the current price. The consensus rating is "Hold".
| Price Target | $48.00 |
| Price Target Difference | 26.62% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.08 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 6 |